Revenue and New Company Growth
Total Q1 revenue of $5.3 billion, up 0.4% year-over-year; New Becton, Dickinson and Company (post-Life Sciences transaction) grew 2.5% YoY, with mid-single-digit growth across ~90% of the NewCo portfolio.
Strong Performance in Key Growth Platforms
Double-digit growth in biologic drug delivery (GLP-1), PureWick, advanced tissue regeneration, and pharmacy automation; high single-digit growth in advanced patient monitoring (APM). Over 80 GLP-1 novel and biosimilar molecules contracted.
Adjusted EPS and Margin Results Beat Expectations
Adjusted EPS of $2.91 (despite a 15.2% YoY decline) and adjusted gross margin of 53.4% were both ahead of the company’s expectations, driven by revenue strength and operational execution.
Significant Corporate Transaction and Cash Deployment
Closed combination of Life Sciences business with Waters via Reverse Morris Trust; received $4.0 billion cash distribution — $2.0 billion to be deployed to share repurchases (ASR) and $2.0 billion to pay down debt.
Shareholder Returns and Balance Sheet Actions
Returned approximately $550 million to shareholders in Q1 (dividends + $250 million buybacks); announced immediate $2.0 billion ASR and $2.0 billion debt repayment from the Waters distribution; net leverage 2.9x with clear plan to move toward 2.5x target.
Operational Productivity and Cost Actions
Becton, Dickinson and Company Excellence drove an 8% productivity improvement in the quarter and $150 million (75%) of the targeted $200 million cost-out program executed, supporting margins and cash flow.
Free Cash Flow and Conversion Improvement
Generated $548 million of free cash flow in the quarter; free cash flow conversion improved to 66% from 59% year-over-year due to working capital discipline and capital efficiency.
Commercial Momentum and Product Launches
Pyxis Pro launch strong with 85% of initial orders from competitive conversions; Alaris saw the strongest quarter of competitive wins since relaunch (category share up ~100 bps in the quarter); launches and submissions include Avitene Flowable (U.S.), SurgiFor (Europe), SurgiFore Pulse (FDA submission), and HemoSphere Stream (targeted release).